This study assessed the percentage of patients after 1 year who persisted on initially prescribed antihypertensive therapy. Medical records of 2416 patients with newly diagnosed hypertension who were prescribed initial antihypertensive monotherapy by general practitioners in Germany, France, and the United Kingdom were evaluated. Comparisons were made among the angiotensin II receptor antagonist (AIIRA) irbesartan, all other antihypertensive classes (including AIIRAs other than irbesartan), and the AIIRA losartan. Patients initiated on the AIIRA irbesartan scored highest with a persistence rate of 60.8%, followed by patients who received all other AIIRA agents with a persistence rate
Introduction
Hypertension is pervasive throughout the industrialised world, affecting 20% to 40% of the adult populations of Europe, Canada, and the United States. [1] [2] [3] [4] [5] Numerous population-based studies have demonstrated that blood pressure reduction is associated with decreased cardiovascular and renal morbidity and mortality. [6] [7] [8] [9] [10] [11] In the last 30 to 40 years, many effective antihypertensive agents have become available. Thus, it is not easily understood why arterial hypertension remains uncontrolled in more than 70% of patients worldwide, 2, 3, 5, 12, 13 even when using the generous, yet outdated cutoff of Ͻ160/95 mm Hg. From a public health point of view, this situation is critical, as hypertension-associated diseases-although to a certain degree preventable-are still the leading cause of death in the Western world.
Poor blood pressure control is a multifactorial issue. These factors include the lack of effective screening strategies, inadequate drug prescribing, and poor patient compliance. Recent research has indicated that persistence, defined as the duration of time a patient remains on a prescribed antihypertensive medication, may also play a crucial role. In 1995, Jones and colleagues 14 published a study with respect to persistence, discontinuation, and changes in treatment following an initial course of antihypertensive therapy in 10 222 hypertensive patients. The study included four classes of agents (diuretics, beta-blockers, calcium channel blockers (CCBs), and angiotensin-converting enzyme (ACEI) inhibitors) to determine 6-month persistence. Continuation with all four classes of agents progressively decreased with some variation between the different drug classes, and at 6 months, 50% to 60% of new treatments had been changed or completely discontinued. These results are particularly important, since the benefits of treating hypertension are not fully attained until a patient has been treated for 4 to 5 years. 15 Consequently, little or no medical benefit can be expected for patients who discontinue their antihypertensive treatment. A longer duration of persistence indicates that both the patient and the clinician are willing to continue with the drug regimen. Persistence is thus a reflection of both tolerability and efficacy.
More data regarding persistence are needed, as most persistence studies have not included the newest class of antihypertensive agents, the angiotensin II receptor antagonists (AIIRAs). The AIIRA class holds great promise, as this class has shown efficacy similar to that of older classes of antihypertensive agents while offering placebo-level tolerability. [16] [17] [18] [19] [20] [21] The present cohort study was undertaken to assess the differences in persistence among all major classes of antihypertensive agents when compared with the AIIRA irbesartan. Comparative clinical trial data show that irbesartan is associated with significantly greater antihypertensive efficacy compared with the two AIIRAs losartan 22, 23 and valsartan. 24 In order to evaluate intraclass differences in persistence among AIIRA agents, irbesartan and losartan were also compared in this study.
Methods

Data sources
Medical record abstraction was performed from IMS MediPlus to identify patients who were newly diagnosed with hypertension and received an initial prescription from an office-based physician for a single antihypertensive agent between 1 October 1997, and 30 September 1998, in Germany, France, and the United Kingdom. The MediPlus databank of IMS Health-an international company-assembles all drug prescriptions, diagnoses, and basic demographic data obtained from the computer systems of hundreds of practices, which represent the characteristics of the general medicine practices in each country. The original interest of establishing MediPlus was to provide data for the pharmaceutical industry for marketing research. For a couple of years, these data have been used for scientific purposes, especially outcomes and pharmacoepidemiologic research. [25] [26] [27] As MediPlus is a quality controlled multiple purpose database, assembling in an unobtrusive manner routinely collected data, there is no differential bias favouring one particular outcome. The data were collected in accordance with data safety regulations of the respective countries and were anonymised.
The study methodology was similar to analogous studies described elsewhere. [28] [29] [30] Entry dates were set to allow 1 year of follow-up for the population overall. The records were collected electronically for 1 year prior to study entry and at least 1 year post study entry and comprised demographic data, diagnoses, all prescribed medications, and prescription history (including dates of prescriptions, generic names, dose, quantity dispensed, and dosing schedule). A sample size of about 400 patients per treatment group was targeted allowing a difference of 10% in the primary end point between the various treatment groups with ␣ р0.05 (two-sided) and a power of 80% to be detected. A difference of 10% in the proportion of persistent patients was considered clinically relevant.
Inclusion and exclusion criteria
Patients who were newly diagnosed with hypertension and prescribed initial treatment with monotherapy were included. Exclusion criteria included a diagnosis of hypertension noted in the record during the 1-year window prior to study entry or a record of an initial prescription for combination antihypertensive therapy. As irbesartan was the primary comparator in this study, patients treated with irbesartan were identified first. Subsequently, hypertensive patients who were prescribed agents from any other antihypertensive class, including diuretics, betablockers, CCBs, ACE inhibitors, or other AIIRAs, were randomly selected and matched to the irbesartan-treated patients by age, sex, and relevant comorbidities, including diabetes, angina, previous stroke, congestive heart failure (CHF), and previous myocardial infarction (MI). The initial antihypertensive agent prescribed during the study period determined the patient's study cohort, and the date that the first prescription was filled became the index date for beginning follow-up.
Primary and secondary study end points
The primary study end point was persistence, defined as the proportion of patients who remained on their initially prescribed monotherapy at 1 year. Secondary study end points included the proportion of patients who required adjunctive therapy, switched to a different monotherapy, or discontinued their initially prescribed agent.
Status was determined by the sequence of filled prescriptions. At 1 year, a patient's status was classified as monotherapy if prescriptions for initial monotherapy had been refilled and no other prescriptions for antihypertensive medications were filled. Dose titration of initial medication was allowed. A patient's status was classified as switched if a prescription for a different antihypertensive agent was filled, after which there were no further prescriptions filled for the original agent. Patients were classified as add-on if prescriptions for the initial agent were refilled and the patient simultaneously filled prescriptions for any additional antihypertensive agent. Patients were classified as discontinued if they had stopped refilling a prescription for any antihypertensive agent for at least 30 days after their antihypertensive medications ran out. Patients who were lost to follow-up, as established by their general practitioner, were classified as discontinued. Since combination therapy is frequently utilised in the treatment of hypertension, an additional analysis was performed looking at patients who remained on their initially prescribed agent either as monotherapy or as part of a combination regimen.
Statistical analyses
Univariate and multivariate analyses were conducted. Any discrepancies of homogeneity among the five study cohorts were analysed with respect to age, sex, and comorbidities, including angina, previous stroke, previous MI, CHF, and diabetes, using 2 -tests and analysis of variance. Tests to determine differences in the primary and secondary end points were conducted using the 2 statistic. The end points were considered significantly different at the 5% level (two-sided).
For the multivariate analysis, a Cox proportional hazard model was calculated, with the duration of time on initially prescribed monotherapy as the dependent variable, and antihypertensive agent, sex, age, and corresponding comorbidities as explanatory factors. The primary end point of persistence with initially prescribed antihypertensive monotherapy was analysed with univariate and multivariate methods for irbesartan, all other antihypertensive classes separately and combined, and losartan. Univariate analyses of the secondary end points were performed for three groups (irbesartan, all other antihypertensive classes, and losartan).
Blood pressure measurements in the follow-up phase were actual readings from general practices, thus the timing and dates of the readings reflect current routine practices of hypertension care. We used the multivariate analysis technique of generalised estimating equations (GEE) for these repeated measures. Generalised estimating equations allow for analysis between dependent and independent variables when serial correlations (time dependency in the current analysis) are present. 31 The GEE analyses were conducted separately for changes in systolic and diastolic blood pressure as well as for each treatment comparison with irbesartan. The analyses were conducted using the SAS 6.12 GENMOD procedure.
Population
From IMS MediPlus, 3026 subjects satisfying the matching criteria were identified. Of this group, 2416 patients met the inclusion criteria as newly diagnosed hypertensive patients with an initial prescription for antihypertensive monotherapy. The cohort was composed of the following groups, based on the initially prescribed agent: ACE inhibitors (n = 333), beta-blockers (n = 441), CCBs (n = 466), diuretics (n = 422), and AIIRAs (n = 754).
The group of patients receiving an AIIRA was composed of patients taking candesartan (n = 82), eprosartan (n = 35), irbesartan (n = 380), losartan (n = 188), or valsartan (n = 69). Baseline data revealed that the groups were similar with respect to age, sex, and the percentage of patients with diabetes, previous MI, previous stroke, angina, or heart failure ( Table 1) . Similarly, no relevant differences were found in baseline blood pressure levels by class of initially prescribed antihypertensive agent ( Table 2) . There were no satistically significant differences at baseline. a Includes candesartan, eprosartan, and valsartan. ACE = angiotension-converting enzyme; AIIRAs = angiotensin II receptor antagonists; CCBs = calcium channel blockers.
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The patients experienced moderate hypertension, with baseline blood pressure measurements above 160/90 mm Hg.
Results
For the total population at 1 year, 46.8% of patients were persistent with initially prescribed antihypertensive monotherapy, 23.8% had been prescribed adjunctive antihypertensive therapy, 12.9% had switched to a different antihypertensive agent, and 16.5% had completely discontinued therapy.
Primary end point
For the primary end point, a wide variation of persistence rates was seen among the various treatment groups (Figure 1) . Patients who were initiated on diuretics scored lowest with a persistence rate of 34.4% at 1 year, whereas those who were initiated on irbesartan scored highest with 60.8%, followed by patients who were initiated on all other AIIRA agents with a persistence rate of 51.3%. ACE inhibi- tors, CCBs, beta-blockers, and losartan were associated with comparable persistence rates, between 42.0% and 49.7%. The differences in persistence rate between irbesartan and the other drugs were statistically significant: P р 0.001 vs diuretics, ACE inhibitors, CCBs, beta-blockers, and losartan, and P р 0.009 vs all other AIIRAs. Figure 2 is a KaplanMeier curve depicting the same data from a multivariate analysis, which demonstrates the progression over time. Figure 3 shows persistence with the initial antihypertensive agent, whether as monotherapy or as part of a combination therapy regimen. Again, diureticbased treatment was associated with the lowest rate of persistence and irbesartan-based treatment with the highest rate of persistence. Secondary end points measured at 1 year are presented in Table 3 . Significantly fewer patients who received irbesartan required adjunctive therapy (16.1%), compared with 25.3% for patients taking all other antihypertensive classes (P = 0.001) and 24.5% for patients taking losartan (P = 0.016). Significantly fewer patients who were initially pre- 
Secondary end points
Figure 3
The percentage of patients who were persistent with an initial antihypertensive agent at 1 year, either as monotherapy or in combination with other agents. *P = 0.001 vs diuretics; P = 0.002 vs ACE inhibitors; P = 0.01 vs CCBs; P = 0.048 vs losartan. ACE = angiotensin-converting enzyme; CCBs = calcium channel blockers; AIIRAs = angiotensin II receptor antagonists. scribed irbesartan switched therapy compared with patients who were prescribed agents from all other antihypertensive classes (9% and 13.6%, respectively; P = 0.013). In addition, significantly fewer patients who were initially prescribed irbesartan discontinued therapy compared with patients who were initially prescribed losartan (14.2% vs 22.9%, respectively; (P = 0.01).
Blood pressure
Since blood pressure readings during follow-up were not available for all subjects, blood pressure reduction was not a predefined end point in this study. However, baseline blood pressure measurements were compared with on-treatment blood pressure measurements in the subgroup of all patients with available blood pressure data. According to a GEE analysis of on-treatment blood pressure values (using 2967 measurements for 717 patients), patients who were initially prescribed irbesartan had a greater average decrease in systolic blood pressure (4.95 mm Hg; P = 0.022) and diastolic blood pressure (3.59 mm Hg; P = 0.053) than patients who were initially prescribed agents from all other anti-hypertensive classes. Similarly, patients who were initially prescribed irbesartan had a greater decrease in both systolic (5.91 mm Hg; P = 0.053) and diastolic blood pressure (4.10 mm Hg; P = 0.090) compared with subjects who were initially prescribed losartan.
Discussion
Nearly three-quarters of adult Americans with hypertension do not have their blood pressure controlled to below 140/90 mm Hg, the measurement value recommended in the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). 15 Control rates in Europe and Asia are even worse. 32 Recent research indicates that lack of persistence may be a major factor in uncontrolled blood pressure. Jones et al 14 examined persistence with various antihypertensive treatments using realworld medical data and found relevant differences among the drug classes, a result subsequently confirmed by other investigators. 30, 33, 34 All published persistence studies report the lowest persistence rates for diuretics. 14, 16, 30, [34] [35] [36] Studies that include the newest antihypertensive class, the AIIRAs, are few. Chaput and Bloom reported superior persistence rates for the AIIRA class, 16, 35 although Benson 36 did not find any superiority for the AIIRA losartan compared with other antihypertensive drug classes. The findings presented here, which analysed for the first time actual practice data from three major European countries, are similar to previous studies using North American data. In the current study, patients who were initially prescribed irbesartan continued therapy longer than patients who initially began therapy with agents from any other antihypertensive class, including other AIIRAs. Patients who were initially prescribed irbesartan were also less likely to switch therapy, require add-on therapy, or discontinue therapy. These findings are in accord with clinical trials that have demonstrated that irbesartan has equal efficacy but better tolerability compared with other antihypertensive classes, [17] [18] [19] [20] [21] [22] and greater efficacy compared with the leading AIIRA agents, losartan and valsartan. 23, 24, 28 Furthermore, increasing the dosage of irbesartan leads on average to an increased blood pressure reduction. Thus patients with an inadequately controlled blood pressure on the lower dosage probably received the higher dosage and thus remained persistent with irbesartan. As the efficacy of losartan cannot be improved in a similar way, losartan is usually combined then with a diuretic; these patients were assessed as 'requiring adjunctive treatment'. The average daily doses of irbesartan (180 mg), losartan (71 mg) and of the various drugs of the other antihypertensive drug classes were within the range of the recommended starting dose to the maximum dose for each agent.
Blood pressure reduction was not a predefined
Journal of Human Hypertension end point, relevant data were only available for 29.7% of all patients and are thus difficult to interpret. With due caution, the results indicate that patients in the irbesartan cohort were not 'underdosed'. As most adverse drug reactions follow a positive dose-adverse response relationship, administering low doses of a drug improves the tolerability profile of a drug, and may thus lead to improved persistence rates. The data presented rather suggest that the greater antihypertensive efficacy afforded by irbesartan compared with other AIIRAs has translated into significantly greater rates of persistence. Many factors contribute to poor hypertension control; however, tolerability and lack of antihypertensive efficacy appear to be the two most critical factors. In a German multicentre investigation of patients who changed antihypertensive therapy in the previous 6 months (n = 1603), the two most important reasons for changing therapy cited by both patients and physicians were inadequate blood pressure control (48%) and adverse effects (30%). 37 A similar survey of physicians, pharmacists, nurses, and hypertensive patients in Spain (n = 2800) also found that lack of efficacy and adverse effects were the primary reasons for switching therapy. 38 Thus, the superior persistence observed for the AIIRAs may be explained by the favourable tolerability profile of this class compared with those of other antihypertensive classes.
Caro and colleagues, 33, 34 using data from all outpatient antihypertensive prescriptions filled in Saskatchewan, Canada, between 1989 and 1994 (n = 79 591), found that frequent changes in the therapeutic regimen, referred to as turbulence, were associated with consistently lower levels of persistence, regardless of the starting agent. The stepped-care approach, which suggests starting therapy with a diuretic or beta-blocking agent, may result in lower long-term persistence with therapy in actual practice than would initiating therapy with an effective, well-tolerated class such as the AIIRAs.
The current data are noteworthy in that subjects who were initially prescribed irbesartan exhibited greater persistence at 1 year compared with subjects who were initially prescribed agents from all other antihypertensive classes, even when subjects were subsequently maintained on a combination therapy regimen. This finding may hold special significance in light of data indicating that the majority of hypertensive patients require combination therapy to adequately control blood pressure. 10 Poor persistence may be associated with adverse clinical events. A study by Elliott 39 found that hypertensive patients who dropped out of treatment had a 63% higher risk of death and first cardiovascular hospitalisation compared with patients who continued with follow-up in a tertiary hypertension clinic. The patients who dropped out of treatment also incurred 74% higher annualised charges for medical costs, mostly because of hospitalisations and emergency room visits. An examination of Journal of Human Hypertension medical claims data by Rizzo and Simons 30 also found that poor persistence was associated with higher health care costs. The increased events associated with poor persistence may stem from both the lack of blood pressure control and the risk of rebound hypertension, which can acutely increase the risk of MI if beta-blockers are abruptly discontinued.
Conclusions
Despite the availability of a multitude of antihypertensive agents, the worldwide prevalence of uncontrolled blood pressure remains alarmingly high. 12 Data from the present cohort study provide a snapshot of real-world prescribing practices that reflects how general practitioners and patients make decisions about antihypertensive therapy based on both patient satisfaction and efficacy concerns. The rate of persistence associated with antihypertensive agents has emerged as an important factor in hypertension control. Our study confirmed previous findings that the choice of the initial antihypertensive agent can have a major impact on long-term persistence.
Generalisable data with respect to persistence can only be gained from real-world settings. Currently, there are no standards for analysing and reporting such observational persistence data. The creation of such standards will be helpful to establish a compendium of reliable, evidence-based data on persistence.
